Log in
Sign up
Immunomic Therapeutics

Immunomic Therapeutics

A biotechnology company developing nucleic acid immunotherapy platform and protein based vaccines

OverviewStructured DataIssuesContributorsActivity
Contents

Immunomic Therapeutics is a company that looks to develop biotechnologies through an immunotherapy platform. The company was founded in 2005, in Rockville, Maryland, United States.

The company studies investigational technologies that can assist in altering how immunotherapy solutions are utilized across a range of diseases. They work with solutions for cancer, allergies, and infectious diseases. The company studies nucleic acid immunotherapy platforms to change how immunotherapies are used for cancer and other uses.

Immunomic Therapeutics is developing treatments such as their ITI-1000 and ITI-1001 for GBM, ITI-2000 for HPV and tumors, ITI-3000 for Merkel Cell Carcinoma, ITI-4000 for NPC and Gastic issues, ITI-5000 for Neoantigens, ITI-6000 for HCC, ITI-7000 for bladder infections, and their ITI-COVID-19 for SARS-CoV-2. They have partnered with entities such as PharmaJet, Zenoq, and Replicate.

They have also created a platform called UNITE (Universal Intracellular Targeted Expression). The platform has lysosomal targeting technology, use adjuvants, antigen selection and optimizations, and offer various delivery methods.

Timeline

No Timeline data yet.

Funding Rounds

Open in Query Tool

Products

Open in Query Tool

Acquisitions

Open in Query Tool

SBIR/STTR Awards

Open in Query Tool

Patents

Open in Query Tool

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

immunomix.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Engineering
Engineering
Vaccine
Vaccine
Immunotherapy
Immunotherapy
Therapeutics
Therapeutics
Biomedical engineering
Biomedical engineering
Consumer biotechnology
Consumer biotechnology
...
Location
United States
United States
Hummelstown, Pennsylvania
Hummelstown, Pennsylvania
Rockville, Maryland
Rockville, Maryland
-1
B2X
B2B
B2B
CEO
‌
William G. Hearl
-1
‌
Dr. Bill Hearl
Founder
‌
Teri Heiland
‌
William G. Hearl
-1
‌
Dr. Bill Hearl
AngelList URL
angel.co/immunomic-...herapeutics
Pitchbook URL
pitchbook.com/profiles.../56451-52
Legal Name
Immunomic Therapeutics, Inc.
Full Address
15010 Broschart Road Suite 250 Rockville, MD 20850-1
CIK Number
1,543,256-1
Investors
Brainchild & Co.
Brainchild & Co.
Life Sciences Greenhouse of Central PA
Life Sciences Greenhouse of Central PA
Minority Angel Investor Network
Minority Angel Investor Network
‌
Mid Atlantic Bio Angels
DUNS Number
623608861
Founded Date
2005
Email Address
info@immunomix.com-1
info@immunomix.com?subject=webpipelineinformationrequestforITI-8000
Phone Number
+13019683501-1
Total Funding Amount (USD)
60,600,000
Latest Funding Round Date
February 2020
Business Model
Licensing
CFO
‌
Eric Winzer
-1
Patents Assigned (Count)
3
Wellfound ID
immunomic-therapeutics
Country
United States
United States
-1

Other attributes

Company Operating Status
Active
Wikidata ID
Q30266635

Find more companies like Immunomic Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Products
Knowledge GraphQuery ToolData RequestsKnowledge StorageAPIPricingEnterpriseChatGPT Plugin
Legal
Terms of ServiceEnterprise Terms of ServicePrivacy Policy
Help
Help centerAPI DocumentationContact Us
By using this site, you agree to our Terms of Service.